Hypoxia-based strategies for angiogenic induction: The dawn of a new era for ischemia therapy and tissue regeneration

Organogenesis

Volumn 9, Issue 4, 2013, Pages 261-272

  Hadjipanayi, Ektoras ^a,b   Schilling, Arndt F ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM BOGENHAUSEN   (Germany)

^c Center for Applied New Technologies in Engineering for Regenerative Medicine (CANTER)   (Germany)

Author keywords

Angiogenesis; Gene transfer; HIF1 stabilization; Hypoxia; Ischaemia; Pre conditioning; Therapy

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANGIOGENESIS; CHRONIC STRESS; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE TRANSFER; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; ISCHEMIC PRECONDITIONING; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TISSUE REACTION; TISSUE REGENERATION;

ANGIOGENESIS; GENE TRANSFER; HIF1 STABILIZATION; HYPOXIA; ISCHAEMIA; PRE-CONDITIONING; THERAPY;

ANIMALS; ANOXIA; GENETIC THERAPY; HUMANS; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION; SIGNAL TRANSDUCTION;

EID: 84891370249     PISSN: 15476278     EISSN: 15558592     Source Type: Journal    
DOI: 10.4161/org.25970     Document Type: Review

References (102)

1. Ho TK, Abraham DJ, Black CM, Baker DM. Hypoxia-inducible factor 1 in lower limb ischemia. Vascular 2006; 14:321-7; PMID:17150152; http://dx.doi.org/10.2310/6670.2006.00056
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389-95; PMID:10742145; http://dx.doi.org/10.1038/74651
3. Loges S, Roncal C, Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost 2009; 7:21-33; PMID:18983480; http://dx.doi.org/10. 1111/j.1538-7836.2008.03203.x
4. Simons M. Angiogenesis: where do we stand now? Circulation 2005; 111:1556-66; PMID:15795364; http://dx.doi.org/10.1161/01.CIR.0000159345.00591.8F
5. Cao Y. Monotherapy versus combination therapy of angiogenic and arteriogenic factors for the treatment of ischemic disorders. Curr Mol Med 2009; 9:967-72; PMID:19925409; http://dx.doi.org/10.2174/156652409789712747
6. Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol 2006; 76:217-57; PMID:17118268; http://dx.doi.org/10.1016/S0070-2153(06)76007-0
7. Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 2010; 86:236-42; PMID:20164116; http://dx.doi.org/10.1093/cvr/cvq045
8. Cassavaugh J, Lounsbury KM. Hypoxia-mediated biological control. J Cell Biochem 2011; 112:735-44; PMID:21328446; http://dx.doi.org/10.1002/jcb.22956
9. Hadjipanayi E, Cheema U, Hopfner U, Bauer A, Machens HG, Schilling AF. Injectable system for spatio-temporally controlled delivery of hypoxia-induced angiogenic signalling. J Control Release 2012; 161:852-60; PMID:22634070; http://dx.doi.org/10.1016/j.jconrel.2012.04.048
10. Levy AP. A cellular paradigm for the failure to increase vascular endothelial growth factor in chronically hypoxic states. Coron Artery Dis 1999; 10:427-30; PMID:10474795; http://dx.doi.org/10.1097/00019501-199909000-00013
11. Pichiule P, LaManna JC. Angiopoietin-2 and rat brain capillary remodeling during adaptation and dead-aptation to prolonged mild hypoxia. J Appl Physiol 2002; 93:1131-9; PMID:12183511
12. Yamamoto A, Takahashi H, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y. Downregulation of angiopoietin-1 and Tie2 in chronic hypoxic pulmonary hypertension. Respiration 2008; 75:328-38; PMID:18073453; http://dx.doi.org/10. 1159/000112432
13. van Weel V, Seghers L, de Vries MR, Kuiper EJ, Schlingemann RO, Bajema IM, Lindeman JH, Delisvan Diemen PM, van Hinsbergh VW, van Bockel JH, et al. Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. Arterioscler Thromb Vasc Biol 2007; 27:1426- 32; PMID:17363691; http://dx.doi.org/10.1161/ ATVBAHA.107.139642
14. Yuan HT, Li XZ, Pitera JE, Long DA, Woolf AS. Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am J Pathol 2003; 163:2289-301; PMID:14633603; http://dx.doi.org/10.1016/S0002-9440(10) 63586-9
15. Tuomisto TT, Rissanen TT, Vajanto I, Korkeela A, Rutanen J, Ylä-Herttuala S. HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. Atherosclerosis 2004; 174:111-20; PMID:15135259; http://dx.doi.org/10. 1016/j.atherosclerosis.2004.01.015
16. Luo F, Wariaro D, Lundberg G, Blegen H, Wahlberg E. Vascular growth factor expression in a rat model of severe limb ischemia. J Surg Res 2002; 108:258-67; PMID:12505050; http://dx.doi.org/10.1006/jsre.2002.6551
17. Olszewska-Pazdrak B, Hein TW, Olszewska P, Carney DH. Chronic hypoxia attenuates VEGF signaling and angiogenic responses by downregulation of KDR in human endothelial cells. Am J Physiol Cell Physiol 2009; 296:C1162-70; PMID:19244479; http://dx.doi.org/10.1152/ajpcell.00533.2008
18. Fraisl P, Aragonés J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 2009; 8:139-52; PMID:19165233; http://dx.doi.org/10.1038/nrd2761
19. Kubo M, Li TS, Suzuki R, Shirasawa B, Morikage N, Ohshima M, Qin SL, Hamano K. Hypoxic preconditioning increases survival and angiogenic potency of peripheral blood mononuclear cells via oxidative stress resistance. Am J Physiol Heart Circ Physiol 2008; 294:H590-5; PMID:18156196; http://dx.doi.org/10.1152/ ajpheart.00856.2007
20. Kubo M, Li TS, Kamota T, Ohshima M, Qin SL, Hamano K. Increased expression of CXCR4 and integrin alphaM in hypoxia-preconditioned cells contributes to improved cell retention and angiogenic potency. J Cell Physiol 2009; 220:508-14; PMID:19415696; http://dx.doi.org/10.1002/jcp.21803
21. Kubo M, Li TS, Kurazumi H, Takemoto Y, Ohshima M, Murata T, Katsura S, Morikage N, Furutani A, Hamano K. Hypoxic preconditioning enhances angiogenic potential of bone marrow cells with aging-related functional impairment. Circ J 2012; 76:986-94; PMID:22293445; http://dx.doi.org/10.1253/circj.CJ-11-0605
22. Hu XY, Yu SP, Fraser JL, Lu ZY, Ogle ME, Wang JA, Wei L. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 2008; 135:799-808; PMID:18374759; http://dx.doi.org/10.1016/j. jtcvs.2007.07.071
23. Wei L, Fraser JL, Lu ZY, Hu X, Yu SP. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis 2012; 46:635-45; PMID:22426403; http://dx.doi.org/10.1016/j.nbd.2012.03.002
24. Barkefors I, Le Jan S, Jakobsson L, Hejll E, Carlson G, Johansson H, Jarvius J, Park JW, Li Jeon N, Kreuger J. Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. J Biol Chem 2008; 283:13905-12; PMID:18347025; http://dx.doi.org/10.1074/jbc.M704917200
25. Hadjipanayi E, Brown RA, Mudera V, Deng D, Liu W, Cheema U. Controlling physiological angiogenesis by hypoxia-induced signaling. J Control Release 2010; 146:309-17; PMID:20538024; http://dx.doi.org/10.1016/j.jconrel.2010.05.037
26. Cheema U, Brown RA, Alp B, MacRobert AJ. Spatially defined oxygen gradients and vascular endothelial growth factor expression in an engineered 3D cell model. Cell Mol Life Sci 2008; 65:177-86; PMID:17994289; http://dx.doi.org/10.1007/s00018-007-7356-8
27. Bhang SH, Cho SW, La WG, Lee TJ, Yang HS, Sun AY, Baek SH, Rhie JW, Kim BS. Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells. Biomaterials 2011; 32:2734-47; PMID:21262528; http://dx.doi.org/10.1016/j.biomaterials.2010.12.035
28. Bhang SH, Lee S, Shin JY, Lee TJ, Kim BS. Transplantation of cord blood mesenchymal stem cells as spheroids enhances vascularization. Tissue Eng Part A 2012; 18:2138-47; PMID:22559333; http://dx.doi.org/10.1089/ten.tea.2011.0640
29. Bhang SH, Lee S, Lee TJ, La WG, Yang HS, Cho SW, Kim BS. Three-dimensional cell grafting enhances the angiogenic efficacy of human umbilical vein endothelial cells. Tissue Eng Part A 2012; 18:310-9; PMID:21902465; http://dx.doi.org/10.1089/ten.tea.2011.0193
30. Park K. Engineered cell/matrix platform for hypoxia-induced angiogenesis. J Control Release 2011; 153:197; PMID:21763733; http://dx.doi.org/10.1016/j. jconrel.2011.07.012
31. Perez-Amodio S, Tra WM, Rakhorst HA, Hovius SE, van Neck JW. Hypoxia preconditioning of tissue-engineered mucosa enhances its angiogenic capacity in vitro. Tissue Eng Part A 2011; 17:1583-93; PMID:21303226; http://dx.doi.org/10. 1089/ten.tea.2010.0429
32. Wang JC, Xia L, Song XB, Wang CE, Wei FC. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells improves survival of ultra-long random skin flap. Chin Med J (Engl) 2011; 124:2507-11; PMID:21933596
33. Stubbs SL, Hsiao ST, Peshavariya HM, Lim SY, Dusting GJ, Dilley RJ. Hypoxic preconditioning enhances survival of human adipose-derived stem cells and conditions endothelial cells in vitro. Stem Cells Dev 2012; 21:1887-96; PMID:22165914; http://dx.doi.org/10.1089/scd.2011.0289
34. Hollenbeck ST, Senghaas A, Komatsu I, Zhang Y, Erdmann D, Klitzman B. Tissue engraftment of hypoxic-preconditioned adipose-derived stem cells improves flap viability. Wound Repair Regen 2012; 20:872-8; PMID:23110692; http://dx.doi.org/10.1111/j.1524-475X.2012.00854.x
35. Di Santo S, Yang Z, Wyler von Ballmoos M, Voelzmann J, Diehm N, Baumgartner I, Kalka C. Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 2009; 4:e5643; PMID:19479066; http://dx.doi.org/10. 1371/journal.pone.0005643
36. Chanyshev B, Shainberg A, Isak A, Chepurko Y, Porat E, Hochhauser E. Conditioned medium from hypoxic cells protects cardiomyocytes against ischemia. Mol Cell Biochem 2012; 363:167-78; PMID:22160856; http://dx.doi.org/10.1007/ s11010-011-1169-7
37. Hsiao ST, Lokmic Z, Peshavariya H, Abberton KM, Dusting GJ, Lim SY, Dilley RJ. Hypoxic conditioning enhances the angiogenic paracrine activity of human adipose-derived stem cells. Stem Cells Dev 2013; 22:1614-23; PMID:23282141; http://dx.doi.org/10.1089/scd.2012.0602
38. Hadjipanayi E, Cheema U, Mudera V, Deng D, Liu W, Brown RA. First implantable device for hypoxia-mediated angiogenic induction. J Control Release 2011; 153:217-24; PMID:21458514; http://dx.doi.org/10.1016/j.jconrel.2011.03.029
39. Cao L, Mooney DJ. Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv Drug Deliv Rev 2007; 59:1340-50; PMID:17868951; http://dx.doi.org/10.1016/j.addr.2007.08.012
40. Komatsu DE, Hadjiargyrou M. Activation of the transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair. Bone 2004; 34:680-8; PMID:15050899; http://dx.doi.org/10.1016/j.bone.2003.12.024
41. Ozduman K, Ozkan A, Yildirim O, Pamir MN, Gunel M, Kilic T. Temporal expression of angiogenesisrelated genes in developing neonatal rodent retina: a novel in vivo model to study cerebral vascular development. Neurosurgery 2010; 66:538-43, discussion 543; PMID:20173549; http://dx.doi.org/10.1227/01.NEU. 0000365615.24973.26
42. Ray PS, Estrada-Hernandez T, Sasaki H, Zhu L, Maulik N. Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis. Mol Cell Biochem 2000; 213:145-53; PMID:11129953; http://dx.doi.org/10.1023/A:1007180518474
43. Hadjipanayi E, Bauer AT, Moog P, Salgin B, Kuekrek H, Fersch B, Hopfner U, Meissner T, Schlüter A, Ninkovic M, et al. Cell-free carrier system for localized delivery of peripheral blood cell-derived engineered factor signaling: towards development of a one-step device for autologous angiogenic therapy. J Control Release 2013; 169:91-102; PMID:23603614; http://dx.doi.org/10.1016/j. jconrel.2013.04.008
44. Hoenig MR, Bianchi C, Sellke FW. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis. Curr Drug Targets 2008; 9:422-35; PMID:18473772; http://dx.doi.org/10.2174/138945008784221215
45. Kaelin WG Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30:393-402; PMID:18498744; http://dx.doi.org/10.1016/j.molcel.2008.04.009
46. Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, Kasprzak KS. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004; 279:40337-44; PMID:15271983; http://dx.doi.org/10.1074/jbc.M403057200
47. Knowles HJ, Tian YM, Mole DR, Harris AL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 2004; 95:162-9; PMID:15192023; http://dx.doi.org/10.1161/01.RES.0000134924. 89412.70
48. Chang EI, Loh SA, Ceradini DJ, Chang EI, Lin SE, Bastidas N, Aarabi S, Chan DA, Freedman ML, Giaccia AJ, et al. Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia. Circulation 2007; 116:2818-29; PMID:18040029; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.715847
49. Takaku M, Tomita S, Kurobe H, Kihira Y, Morimoto A, Higashida M, Ikeda Y, Ushiyama A, Hashimoto I, Nakanishi H, et al. Systemic preconditioning by a prolyl hydroxylase inhibitor promotes prevention of skin flap necrosis via HIF-1-induced bone marrow-derived cells. PLoS One 2012; 7:e42964; PMID:22880134; http://dx.doi.org/10.1371/journal.pone.0042964
50. Raghunath M, Sy Wong Y, Farooq M, Ge R. Pharmacologically induced angiogenesis in transgenic zebrafish. Biochem Biophys Res Commun 2009; 378:766-71; PMID:19068208; http://dx.doi.org/10.1016/j.bbrc.2008.11.127
51. Mace KA, Yu DH, Paydar KZ, Boudreau N, Young DM. Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen 2007; 15:636-45; PMID:17971009; http://dx.doi.org/ 10.1111/j.1524-475X.2007.00278.x
52. Botusan IR, Sunkari VG, Savu O, Catrina AI, Grünler J, Lindberg S, Pereira T, Ylä-Herttuala S, Poellinger L, Brismar K, et al. Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A 2008; 105:19426-31; PMID:19057015; http://dx.doi.org/10.1073/ pnas.0805230105
53. Milkiewicz M, Pugh CW, Egginton S. Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J Physiol 2004; 560:21-6; PMID:15319416; http://dx.doi.org/10.1113/jphysiol.2004. 069757
54. Nangaku M, Izuhara Y, Takizawa S, Yamashita T, Fujii-Kuriyama Y, Ohneda O, Yamamoto M, van Ypersele de Strihou C, Hirayama N, Miyata T. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 2007; 27:2548-54; PMID:17932321; http://dx.doi.org/10.1161/ATVBAHA.107.148551
55. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita GY, Gregory RJ, Isner JM. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102:2255-61; PMID:11056102; http://dx.doi.org/10.1161/01.CIR. 102.18.2255
56. Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, Chang H. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 2002; 54:576-83; PMID:12031703; http://dx.doi.org/10.1016/S0008- 6363(02)00259-6
57. Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA, Cheng SH, Gregory RJ, Jiang C. Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am J Physiol Cell Physiol 2005; 288:C314-20; PMID:15496478; http://dx.doi.org/10.1152/ajpcell.00374.2004
58. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005; 46:2116-24; PMID:16325051; http://dx.doi.org/10.1016/j. jacc.2005.08.045
59. Heinl-Green A, Radke PW, Munkonge FM, Frass O, Zhu J, Vincent K, Geddes DM, Alton EW. The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia. Eur Heart J 2005; 26:1327-32; PMID:15821009; http://dx.doi.org/10.1093/eurheartj/ehi223
60. Matsuda T, Abe T, Wu JL, Fujiki M, Kobayashi H. Hypoxia-inducible factor-1alpha DNA induced angiogenesis in a rat cerebral ischemia model. Neurol Res 2005; 27:503-8; PMID:15978176; http://dx.doi.org/10.1179/016164105X25144
61. Pajusola K, Künnapuu J, Vuorikoski S, Soronen J, André H, Pereira T, Korpisalo P, Ylä-Herttuala S, Poellinger L, Alitalo K. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 2005; 19:1365-7; PMID:15958522
62. Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxiainducible factor-1alpha. Genes Dev 2001; 15:2520-32; PMID:11581158; http://dx.doi.org/10.1101/gad.914801
63. Trentin D, Hall H, Wechsler S, Hubbell JA. Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc Natl Acad Sci U S A 2006; 103:2506-11; PMID:16477043; http://dx.doi.org/10.1073/pnas.0505964102
64. Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV, Nastai M, Semenza GL, Harmon JW. Age-dependent impairment of HIF-1alpha expression in diabetic mice: Correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol 2008; 217:319-27; PMID:18506785; http://dx.doi.org/10.1002/jcp.21503
65. Patel TH, Kimura H, Weiss CR, Semenza GL, Hofmann LV. Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 2005; 68:144-54; PMID:15921668; http://dx.doi.org/10.1016/j.cardiores.2005.05.002
66. Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marcé M, Semenza GL. Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A 2009; 106:18769-74; PMID:19841279; http://dx.doi.org/10.1073/pnas.0910561106
67. Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, Zhang H, Strazza M, Rey S, Savino L, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 2007; 101:1310-8; PMID:17932327; http://dx.doi.org/10.1161/CIRCRESAHA.107.153346
68. Rey S, Lee K, Wang CJ, Gupta K, Chen S, McMillan A, Bhise N, Levchenko A, Semenza GL. Synergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia. Proc Natl Acad Sci U S A 2009; 106:20399-404; PMID:19948968; http://dx.doi.org/10. 1073/pnas.0911921106
69. Kajiwara H, Luo Z, Belanger AJ, Urabe A, Vincent KA, Akita GY, Cheng SH, Mochizuki S, Gregory RJ, Jiang C. A hypoxic inducible factor-1 alpha hybrid enhances collateral development and reduces vascular leakage in diabetic rats. J Gene Med 2009; 11:390-400; PMID:19291676; http://dx.doi.org/10.1002/jgm.1318
70. Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007; 115:1234-43; PMID:17309918
71. Li M, Liu C, Bin J, Wang Y, Chen J, Xiu J, Pei J, Lai Y, Chen D, Fan C, et al. Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle. Microvasc Res 2011; 81:26-33; PMID:20937289; http://dx.doi.org/10.1016/j.mvr.2010.09.008
72. Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A, Barshack I, Bangio L, Hodish I, Greenberger S, et al. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol Ther 2008; 16:1927-36; PMID:18797451; http://dx.doi.org/10.1038/mt.2008.191
73. Bhang SH, Kim JH, Yang HS, La WG, Lee TJ, Kim GH, Kim HA, Lee M, Kim BS. Combined gene therapy with hypoxia-inducible factor-1α and heme oxygenase-1 for therapeutic angiogenesis. Tissue Eng Part A 2011; 17:915-26; PMID:20979535; http://dx.doi.org/10.1089/ten.tea.2010.0493
74. Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets 2010; 11:1551-70; PMID:20704546; http://dx.doi.org/ 10.2174/1389450111009011551
75. Ben-Shoshan J, Schwartz S, Luboshits G, Maysel-Auslender S, Barzelay A, Polak-Charcon S, Tzahor E, Barshack I, Barak A, Levkovitch-Verbin H, et al. Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells 2008; 26:2634-43; PMID:18687993; http://dx.doi.org/10.1634/stemcells.2008-0369
76. Jiang M, Wang B, Wang C, He B, Fan H, Shao Q, Gao L, Liu Y, Yan G, Pu J. In vivo enhancement of angiogenesis by adenoviral transfer of HIF-1alpha-modified endothelial progenitor cells (Ad-HIF-1alpha-modified EPC for angiogenesis). Int J Biochem Cell Biol 2008; 40:2284-95; PMID:18450499; http://dx.doi.org/10.1016/j.biocel.2008.03.012
77. Wu W, Chen X, Hu C, Li J, Yu Z, Cai W. Transplantation of neural stem cells expressing hypoxia-inducible factor-1alpha (HIF-1alpha) improves behavioral recovery in a rat stroke model. J Clin Neurosci 2010; 17:92-5; PMID:19913430; http://dx.doi.org/10.1016/j.jocn.2009.03.039
78. Zou D, Zhang Z, Ye D, Tang A, Deng L, Han W, Zhao J, Wang S, Zhang W, Zhu C, et al. Repair of criticalsized rat calvarial defects using genetically engineered bone marrow-derived mesenchymal stem cells overexpressing hypoxia-inducible factor-1α. Stem Cells 2011; 29:1380-90; PMID:21774039
79. Kim SH, Moon HH, Kim HA, Hwang KC, Lee M, Choi D. Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Mol Ther 2011; 19:741-50; PMID:21245851; http://dx.doi.org/10.1038/mt.2010.301
80. Hastings CL, Kelly HM, Murphy MJ, Barry FP, O'Brien FJ, Duffy GP. Development of a thermoresponsive chitosan gel combined with human mesenchymal stem cells and desferrioxamine as a multimodal pro-angiogenic therapeutic for the treatment of critical limb ischaemia. J Control Release 2012; 161:73-80; PMID:22562065; http://dx.doi.org/10.1016/j.jconrel.2012.04.033
81. Cheema U, Hadjipanayi E, Tammi N, Alp B, Mudera V, Brown RA. Identification of key factors in deep O2 cell perfusion for vascular tissue engineering. Int J Artif Organs 2009; 32:318-28; PMID:19670183
82. Streeter I, Cheema U. Oxygen consumption rate of cells in 3D culture: the use of experiment and simulation to measure kinetic parameters and optimise culture conditions. Analyst 2011; 136:4013-9; PMID:21804989; http://dx.doi.org/10.1039/c1an15249a
83. Rong ZM, Cheema U, Vadgama P. Needle enzyme electrode based glucose diffusive transport measurement in a collagen gel and validation of a simulation model. Analyst 2006; 131:816-21; PMID:16802027; http://dx.doi.org/10.1039/ b600334f
84. Cheema U, Rong Z, Kirresh O, Macrobert AJ, Vadgama P, Brown RA. Oxygen diffusion through collagen scaffolds at defined densities: implications for cell survival in tissue models. J Tissue Eng Regen Med 2012; 6:77-84; PMID:21312340; http://dx.doi.org/10.1002/term.402
85. Cheema U, Alekseeva T, Abou-Neel EA, Brown RA. Switching off angiogenic signalling: creating channelled constructs for adequate oxygen delivery in tissue engineered constructs. Eur Cell Mater 2010; 20:274-80, discussion 280-1; PMID:20927711
86. Wu C, Zhou Y, Fan W, Han P, Chang J, Yuen J, Zhang M, Xiao Y. Hypoxia-mimicking mesoporous bioactive glass scaffolds with controllable cobalt ion release for bone tissue engineering. Biomaterials 2012; 33:2076-85; PMID:22177618; http://dx.doi.org/10.1016/j.biomaterials.2011.11.042
87. McDonough MA, Li V, Flashman E, Chowdhury R, Mohr C, Liénard BM, Zondlo J, Oldham NJ, Clifton IJ, Lewis J, et al. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci U S A 2006; 103:9814-9; PMID:16782814; http://dx.doi.org/10.1073/ pnas.0601283103
88. Hewitson KS, McNeill LA, Schofield CJ. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des 2004; 10:821-33; PMID:15032687; http://dx.doi.org/10.2174/ 1381612043452884
89. Kim HA, Kim K, Kim SW, Lee M. Transcriptional and post-translational regulatory system for hypoxia specific gene expression using the erythropoietin enhancer and the oxygen-dependent degradation domain. J Control Release 2007; 121:218-24; PMID:17628167; http://dx.doi.org/10.1016/j.jconrel.2007.05.036
90. Lee S, Kim K, Kim HA, Kim SW, Lee M. Augmentation of erythropoietin enhancer-mediated hypoxia-inducible gene expression by co-transfection of a plasmid encoding hypoxia-inducible factor 1alpha for ischemic tissue targeting gene therapy. J Drug Target 2008; 16:43-50; PMID:18172819; http://dx.doi.org/10. 1080/10611860701699693
91. McTiernan CF, Mathier MA, Zhu X, Xiao X, Klein E, Swan CH, Mehdi H, Gibson G, Trichel AM, Glorioso JC, et al. Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther 2007; 14:1613-22; PMID:17851548; http://dx.doi.org/10.1038/sj. gt.3303020
92. Mughal NA, Russell DA, Ponnambalam S, Homer-Vanniasinkam S. Gene therapy in the treatment of peripheral arterial disease. Br J Surg 2012; 99:6-15; PMID:22068822; http://dx.doi.org/10.1002/bjs.7743
93. Hao X, Månsson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, Brodin LA, Sylvén C. Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model. Cardiovasc Res 2007; 73:481-7; PMID:17134685; http://dx.doi.org/10.1016/j.cardiores.2006.10.011
94. Yockman JW, Kastenmeier A, Erickson HM, Brumbach JG, Whitten MG, Albanil A, Li DY, Kim SW, Bull DA. Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction. J Control Release 2008; 132:260-6; PMID:18662730; http://dx.doi.org/10.1016/j.jconrel.2008.06.024
95. Müller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007; 73:453-62; PMID:17097076; http://dx.doi.org/10.1016/j.cardiores.2006.09.021
96. Yockman JW, Choi D, Whitten MG, Chang CW, Kastenmeier A, Erickson H, Albanil A, Lee M, Kim SW, Bull DA. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Ther 2009; 16:127-35; PMID:18784748; http://dx.doi.org/10.1038/gt. 2008.146
97. Christensen LV, Chang CW, Yockman JW, Conners R, Jackson H, Zhong Z, Feijen J, Bull DA, Kim SW. Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery. J Control Release 2007; 118:254-61; PMID:17276536; http://dx.doi.org/10.1016/j.jconrel.2006.12.018
98. Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, Fowler AA 3rd. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 2006; 98:133-40; PMID:16306444; http://dx.doi.org/10.1161/01.RES.0000197816.63513.27
99. Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler AA 3rd. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol 2007; 293:H1571-80; PMID:17545479; http://dx.doi.org/10.1152/ajpheart.00291.2007
100. Wu S, Nishiyama N, Kano MR, Morishita Y, Miyazono K, Itaka K, Chung UI, Kataoka K. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. Mol Ther 2008; 16:1227-34; PMID:18500250; http://dx.doi.org/10.1038/mt.2008.90
101. Huang M, Chan DA, Jia F, Xie X, Li Z, Hoyt G, Robbins RC, Chen X, Giaccia AJ, Wu JC. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 2008; 118(Suppl):S226-33; PMID:18824759; http://dx.doi.org/10.1161/ CIRCULATIONAHA.107.760785
102. Okamoto N, Tanaka A, Jung K, Karasawa K, Orito K, Matsuda A, Amagai Y, Oida K, Ohmori K, Matsuda H. Silencing of int6 gene restores function of the ischaemic hindlimb in a rat model of peripheral arterial disease. Cardiovasc Res 2011; 92:209-17; PMID:21771896; http://dx.doi.org/10.1093/cvr/cvr203